Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.~* Requiring hormonal treatment.~* Postmenopausal women (woman who has stopped having menstrual periods)~Exclusion Criteria:~* Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.~* Treatment with more than one previous regimen of endocrine therapy for advanced BC.~* An existing condition that prevents compliance.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Fulvestrant 250 mg (intramuscular injection 250 mg)
- 2 (Type: EXPERIMENTAL): Fulvestrant 250 mg (+ 250 mg loading regimen)
- 3 (Type: EXPERIMENTAL): Fulvestrant 500 mg (intramuscular injection 500 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).